The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | The practical challenges of using novel CAR T-cell agents
David Maloney, BSc, MD, PhD, of Fred Hutchinson Cancer Research Center, Seattle, WA, gives an overview of the practical challenges of using novel CAR T-cell agents. He explains that many patients may have major complications with cytokine release syndrome or neurotoxicity, which must be treated with specialized treatments, such as tocilizumab. Due to this, these agents are currently being rolled out in a measured fashion to limit and monitor these complications. Recorded at American Society of Hematology 2017 Annual Meeting, held in Atlanta, GA.
